Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-08-22 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the initiation of development for a novel formulation of Bucillamine by Revive Therapeutics. It discusses research agreements, potential therapeutic uses, regulatory incentives, and future plans for clinical and commercial development. There are no financial statements, quarterly or annual results, nor detailed financial data or management analysis. The document is informational about a new project and strategic direction, typical of a corporate announcement or update. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. It is a company announcement about a development initiative, which aligns best with a Regulatory Filings (RNS) classification as a general regulatory announcement or corporate update that does not fit other specific categories.
2023-08-22 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of a provisional patent application related to Bucillamine for treatment of chemical warfare agent exposure. It contains no financial data, no regulatory filings, no management or board changes, no earnings or annual report content, and no detailed investor presentation. It is a corporate announcement about intellectual property and strategic plans, typical of a general regulatory or corporate news release. The document is about 5118 characters, which is relatively short and does not contain substantive financial or operational report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2023-07-28 English
News release - English.pdf
Regulatory Filings
2023-07-06 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, signed by the CEO, certifying the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. It is primarily an officer certification letter confirming the accuracy and completeness of the interim filings, without containing actual financial data or substantive financial analysis itself. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR) they reference.
2023-05-31 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Revive Therapeutics Ltd. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended March 31, 2023. The document is a certification letter, not the interim report itself, and contains no substantive financial data or analysis. It references the interim filings but does not include them. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS), not as the interim report (IR). The document length is short (3031 characters), consistent with a certification letter rather than a full report.
2023-05-31 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Interim Management’s Discussion and Analysis – Quarterly Highlights for the three and nine months ended March 31, 2023' and is dated May 25, 2023. It explicitly states it is an Interim MD&A prepared in compliance with Form 51-102F1 and National Instrument 51-102, which are Canadian continuous disclosure obligations. The document contains detailed discussion of business operations, liquidity, capital resources, forward-looking statements, and references to unaudited condensed interim consolidated financial statements for the three and nine months ended March 31, 2023. This matches the definition of an Interim / Quarterly Report (IR), which must contain substantive financial data and analysis for a period shorter than a full fiscal year. The document is about 15,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the correct classification is IR with high confidence. 9M 2023
2023-05-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.